공황장애 환자에서 파록세틴 약물 치료가 바이오피드백 측정 변수들에 미치는 영향 = Effect of Pharmacotherapy with Paroxetine on Biofeedback Measurement Variables in Panic Disorder Patients

다국어 초록 (Multilingual Abstract)

Objective
There have been much effort to find reliable indicators predicting treatment response in panic disorder. This study aimed to find the effect of pharmacotherapy on biofeedback measurement variables in panic disorder patients.
Method
We recruited 38 panic disorder patients(M;25, F;13) in the Samsung Medical Center, who were diagnosed by the ADIS-IV(Anxiety Disorder Interview Schedule-IV), and 33 normal control subjects (M;21 F;12 ). Panic patients were treated with paroxetine for 3 months. All subjects were assessed on forearm and frontal electromyography(EMG), electrodermal response(EDR), and skin temperature in baseline, stress, recovery phases using the Procomp & Biograph biofeedback instrument. Psychological measures such as Hamilton anxiety rating scale(HAM-A), Hamilton depression rating scale(HAM-D), Beck depression inventory( BDI), Spielberger state-trait anxiety inventory(STAI-S, STAI-T), and Anxiety sensitivity index(ASI) were also assessed. All measurements were performed at the beginning of the study and after 3 months of paroxetine treatment.
Result
Panic patients had significantly higher scores on psychological measures such as HAM-A, HAM-D, BDI, STAI-S, STAI-T, and ASI(all p values<0.001) before treatment. After 3months of treatment, panic patients showed significant improvement on baseline EDR(z=-2.824, p=0.005), stress EDR(z=-2.691, p=0.007), and recovery EDR (z=-3.416, p=0.001). They also showed significant improvement on HAM-A, HAM-D, BDI, STAI-S, STAI-T, and ASI(all p values <0.001) after treatment.
Conclusion
Electrodermal response, one of the biofeedback measurement variables, was suggested to be the possible indicator predicting treatment response in panic disorder.

참고문헌 (Reference)

1 "the Asesment of anxiety states by rating" 32 : 50-55, 1960

2 Rosenberg R, "imipramine and placebo treatment of panic disorder" 46-52, actapsychiatrscandsuppl1991

3 "The nature and treatment of anxiety and panic" Guilford press 1988

4 "The many faces of Pan Psychological and physiological differences among three types of panic attacks" 347-357, 1992

5 Eaton WW, "The epidemiology of panic" John Wiley & Sons. Inc 50-65, 1995

6 Kaplan HI, "Synopsis of psychiatry eighth ed" Bal-timore, Williams and Wilkins 594-603, 1998

7 DiNardo PA, "Reliability of DSM-I anxiety disorder categories using a new structured interview" 1070-1074, 1983

8 Kopp MS, "Psychophysiologic charateristics of anxiety patients and controls" 52 : 74-79, 1989

9 "Psychological characteristics and biofeedback mitigation in preadolescent with eating disorders" 42 : 76-81, 2000

10 "Psychoeducation in panic disorder patients:Efect of a self-information booklet in a ran-domized,masked-rater study" 16 : 71-76, 2002

11 Scheibe G, "Pretreatment anxiety level as diferential predictor in outpatients with panic disorder" 42 : 1090-1094, 1992

12 Woodman CL, "Prediction of response to alprazolam and placebo in patients with panic disorder" 30 : 5-13, 1994

13 Sharp DM, "Predicting treatment outcome for panic disorder and agoraphobia in primary care" 6 : 336-348, 19

14 "Placebo response in panic disorder:a review" 9 : 123-127, 1994

15 Merz WA, "Placebo response in panic disorder:a review" 9 : 123-127, 1994

16 Albus M, "Panic disorder with or without concomitant depresion 5 years after treatment:a prospective follow-up" 34 : 109-115, 1995

17 Eaton WW, "Panic and panic disorder in the United States" 151 : 413-420, 194

18 "Manual for the State-Trait Anxiety Inventory" 1983

19 Rickels K, "Maintenance drug treatment for panic disorder Short- and long-term outcome after drug taper" 61-68, 1993

20 "Handbook of complementary and alternative me-dicine" Academic Press 2002

21 "Expresion of altered α2-adrenergic phenotype traits in nor-motensive humans at genetic risk of hereditary(essential)hy-pertension" 16 : 779-792, 1998

22 "Emotion in criminal offenders with psychopathy and borderline personality disorder" 58 : 737-745, 2001

23 Kopp MS, "Electrodemal characteristics in psychosomatic pa-tient group" 2 : 73-85, 1984

24 "Beta 2-adrenergic receptor characteristics in slep apnea patients" 18 : 39-42, 1995

25 "Anxiety sen-sitivity,anxiety frequency and the prediction of fearfulness" 24 : 1-8, 1986

26 "An in-ventory for measuring depresion" 4 : 561-571, 1961

27 Liebowitz MR, "Alprazolam in the treatment of panic disor-ders" 6 : 13-20, 1986

28 "A rating scale for depresion" 23 : 56-62, 1960

29 "A practitioners guide" Schwartz MS and associates editors 75-7, 1995

30 Faravelli C, "5-year prospective,natu-ralistic follow-up study of panic disorder" 36 : 271-277, 1995

31 Scheibe G, "1997 Predictors and outcome in panic disorder a 2-year prospective follow-up study" 30 : 177-184, 1997